Health Care [ 4/12 ] | Biotechnology [ 18/72 ]
NASDAQ | Common Stock
CureVacN. V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA).
It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which has completed Phase 1 clinical trial for rabies virus glycoprotein; and CVSQIV, which is in Phase 1 clinical trial against influenza, as well as vaccine for lassa fever, yellow fever, respiratory syncytial virus, rotavirus, malaria, and universal influenza.
The company also develops RNA-based cancer therapies, including CV8102, which is in Phase 1 clinical trial for treating cutaneous melanoma and adenoidcystic carcinoma, as well as squamous cell cancer of skin, head, and neck.
CureVacN. V. was founded in 2000 and is headquartered in Tübingen, Germany.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Jun 18, 24 | -0.39 Decreased by -44.44% | -0.25 Decreased by -56.00% |
| Mar 12, 24 | -0.42 Increased by +36.36% | -0.20 Decreased by -110.00% |
| Nov 14, 23 | -0.22 Increased by +12.00% | -0.23 Increased by +4.35% |
| Aug 17, 23 | -0.30 Increased by +3.23% | -0.24 Decreased by -25.00% |
| May 30, 23 | -0.27 Decreased by -237.50% | -0.34 Increased by +20.59% |
| Dec 31, 22 | -0.66 Increased by +14.29% | -0.34 Decreased by -94.12% |
| Nov 16, 22 | -0.25 Increased by +69.70% | -0.27 Increased by +7.41% |
| Aug 18, 22 | -0.31 Increased by +6.06% | -0.26 Decreased by -19.23% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 23 | 16.48 M Increased by +47.01% | -48.68 M Decreased by -2.34% | Decreased by -295.34% Increased by +30.39% |
| Jun 30, 23 | 7.58 M Decreased by -62.38% | -67.41 M Decreased by -17.07% | Decreased by -889.48% Decreased by -211.19% |
| Mar 31, 23 | 11.69 M Decreased by -71.65% | -128.78 M Decreased by -6.55 K% | Decreased by -1.10 K% Decreased by -23.36 K% |
| Dec 31, 22 | 11.69 M Decreased by -71.65% | -128.78 M Decreased by -6.55 K% | Decreased by -1.10 K% Decreased by -23.36 K% |
| Sep 30, 22 | 11.21 M Decreased by -61.79% | -47.57 M Increased by +66.97% | Decreased by -424.26% Increased by +13.57% |
| Jun 30, 22 | 20.15 M Decreased by -10.04% | -57.58 M Increased by +62.13% | Decreased by -285.83% Increased by +57.90% |
| Mar 31, 22 | 41.23 M Increased by +587.08% | -1.94 M Increased by +96.62% | Decreased by -4.70% Increased by +99.51% |
| Dec 31, 21 | 41.23 M Increased by +587.08% | -1.94 M Increased by +96.62% | Decreased by -4.70% Increased by +99.51% |